Dipeptides deliver

Antonio, Jose
May 1998
Joe Weider's Muscle & Fitness;May98, Vol. 59 Issue 5, p52
Presents information on dipeptides. What is a dipeptide; Information on the advantages of dipeptides to bodybuilder; How they work.


Related Articles

  • Some disagreement over which heart attack patients should get ACE inhibitors.  // Modern Medicine;Nov94, Vol. 62 Issue 11, p16 

    Reports on the disagreement by speakers at a joint meeting of the World Congress of Cardiology and European Society of Cardiology in Berlin over which heart attack patient should get angiotensin-converting enzyme (ACE) inhibitors. GSS-3 study; ISIS-4 trial; Acute Infarction Ramipril Efficacy...

  • ACE inhibitor for hypertension.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p26 

    Reports that the angiotensin-converting enzyme (ACE) inhibitor moexipril HCL has been approved for treating hypertension. Suggested starting dosage; Contraindications; Side effects.

  • Avoid stopping digoxin in patients who are also on ACE inhibitors. Packer, M.; Gheorgiade, M. // Geriatrics;Nov93, Vol. 48 Issue 11, p87 

    Presents the findings on the effects of digoxin withdrawal in 178 clinically stable patients. Continued administration of digoxin for patients undergoing angiotensin-converting enzyme therapy; Frequency of the occurrence of side effects; Study published at a 1993 issue of the `New England...

  • Angiotensin-converting Enzyme Inhibitors as Inducers of Adverse Cutaneous Reactions. Steckelings, U. M.; Artuc, M.; Wollschläger, T.; Wiehstutz, S.; Henz, B. M. // Acta Dermato-Venereologica;Oct/Nov2001, Vol. 81 Issue 5, p321 

    Since adverse effects due to angiotensin-converting enzyme (ACE) inhibitors frequently occur in cutaneous locations, this review summarizes the spectrum of expected and unexpected adverse effects of these drugs, possible associated mechanisms, and their basic functions for dermatologists. ACE...

  • Research Briefs: Night time dosing.  // GP: General Practitioner;5/20/2011, p10 

    The article reports that taking angiotensin-converting enzyme at night is more effective than taking the dose in the morning.

  • VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts. Shimizu, Toshihiro; Okamoto, Hiroshi; Chiba, Satoru; Matsui, Yutaka; Sugawara, Takeshi; Akino, Masatoshi; Nan, Jia; Kumamoto, Hideki; Onozuka, Hisao; Mikami, Taisei; Kitabatake, Akira // Cardiovascular Research;Apr2003, Vol. 58 Issue 1, p203 

    Objective: Coronary microcirculation plays an important role in the progression of cardiac remodeling. Among angiogenic factors, it has been reported that angiotensin II may contribute to neovascularization. However, it is unknown whether inhibition of the renin�angiotensin system...

  • Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Yuan, Zuyi; Kishimoto, Chiharu; Shioji, Keisuke; Nakamura, Hajime; Yodoi, Junji; Sasayama, Shigekake // Cardiovascular Research;Sep2002, Vol. 55 Issue 2, p320 

    Objective: Thioredoxin (TRX) is a redox regulatory protein that protects cells from various stresses. Angiotensin-converting enzyme (ACE) inhibitor was reported to enhance endogenous antioxidant enzyme activities. This study was carried out to investigate whether temocapril, a novel...

  • An ACE structure. Hooper, Nigel M.; Turner, Anthony J. // Nature Structural Biology;Mar2003, Vol. 10 Issue 3, p155 

    Discusses the structure of one of two catalytic domains of angiotensin converting enzyme (ACE). Review of related literature with regard to the structures of the testicular isoform of ACE; Functions of ACE; Details on the relationship of ACE with other zinc metallopeptidases.

  • Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. Natesh, Ramanathan; Schwager, Sylva L. U.; Sturrock, Edward D.; Acharya, K. Ravi // Nature;1/30/2003, Vol. 421 Issue 6922, p551 

    Angiotensin-converting enzyme (ACE) has a critical role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II. Inhibitors of ACE are a first line of therapy for hypertension, heart failure,...

  • Structure-based drug design: An ACE surprise. Frantz, Simon // Nature Reviews Drug Discovery;Apr2003, Vol. 2 Issue 4, p252 

    Reports on the determination of the X-ray structure of angiotensin converting enzyme (ACE) and its complex with the widely used ACE inhibitor lisinopril at high resolution. Resemblance of ACE to rat neurolysin and Pyrococcus furiosus carboxypeptidase.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics